tirzepatide nejm In an earlier analysis of the SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight Tirzepatide vs Semaglutide: 2025 NEJM
Pay in 4 interest-free payments of $5.75 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5
![tirzepatide nejm In an earlier analysis of the SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight Tirzepatide vs Semaglutide: 2025 NEJM](https://belite.com/wp-content/uploads/2025/05/Tirzepatide-vs.-Semaglutide.png)
![tirzepatide nejm In an earlier analysis of the SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight Tirzepatide vs Semaglutide: 2025 NEJM](https://external-preview.redd.it/tirzepatide-versus-semaglutide-once-weekly-in-patients-with-v0-rD-uM3Pq0oD6X2CsLJLa70i7pwJ6uT7JigwFLfHipnQ.jpeg?width=640&crop=smart&auto=webp&s=d5dabf5d2692e05878ff7d73ebb54ad582302b68)
![tirzepatide nejm In an earlier analysis of the SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight Tirzepatide vs Semaglutide: 2025 NEJM](https://belite.com/wp-content/uploads/2025/06/July-2025-Blog-Post-Belite.png)





















